Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

KalVista Says UK MHRA Awarded Innovation Passport For Sebetralstat, An Investigational Novel, Oral Plasma Kallikrein Inhibitor For On-demand Treatment Of Hereditary Angioedema

Author: Benzinga Newsdesk | February 20, 2024 07:56am

The Innovation Passport is the first step in the UK's Innovative Licensing and Access Pathway (ILAP), which is designed to accelerate a product's time to market and facilitate patient access to innovative medicines.

Posted In: KALV


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist